Availability and access to orphan drugs for rare cancers in Bulgaria: analysis of delays and public expenditures
This repository contains the data and code used for the article "Availability and access to orphan drugs for rare cancers in Bulgaria: analysis of delays and public expenditures" The repository is organized into the following main directories:
📦 Availability and access to orphan drugs for rare cancers in Bulgaria
┣ 📂 ./data
┃ ┣ 📂 ./cost_hospital_level
┃ ┣ 📂 ./shapefiles
┃ ┣ 📜 d.csv
┃ ┗ 📜 ema.csv
┣ 📂 ./figures
┣ 📂 ./scripts
┃ ┣ 📜 analysis.R
┃ ┗ 📜 data-merging-and-cleaning.R
┗ 📜 README.md
./data
: contains the raw data used in the analysis./cost_hospital_level
: contains data on the costs of orphan cancer drugs at the hospital level for each period of the study in excel format./shapefiles
: contains shapefiles for Bulgari used in the analysisd.csv
: contains cleaned and merged data from the./cost_hospital_level
using thedata-merging-and-cleaning.R
script. The data contains the following columns:region
: region of the hospital where the expenditure was madehospital
: name of the hospitalatc
: Anatomical Therapeutic Chemical Classification System codeаmount
: amount of the drugn_in_package
: number of units in the packageicd
: International Classification of Diseases coden_patients
: number of patientsmarket_name
: name of the drugpackages
: number of packagescosts
: costs of the drug (in BGN)date
: date of the expenditureinn
: International Nonproprietary Nameyear
: year of the expendituremonth
: month of the expenditurequarter
: quarter of the expenditure
ema.csv
: The EPAR data from the European Medicines Agency (EMA) contains the following columns:category
: category of the drug (human or veterinary)market_name
: name of the drugTherapeutic area
: therapeutic area of the druginn
: International Nonproprietary NameActive substance
: active substance of the drugProduct number
: product numberPatient safety
: patient safetystatus
: status of the drugatc
: Anatomical Therapeutic Chemical Classification System codeAdditional monitoring
: additional monitoringGeneric
: genericBiosimilar
: biosimilarConditional approval
: conditional approvalExceptional circumstances
: exceptional circumstancesAccelerated assessment
: accelerated assessmentOrphan medicine
: orphan medicine (yes or no)Marketing authorisation date
: date of marketing authorisationDate of refusal of marketing authorisation
: date of refusal of marketing authorisationMarketing authorisation holder/company name
: marketing authorisation holder/company nameHuman pharmacotherapeutic group
: human pharmacotherapeutic groupVet pharmacotherapeutic group
: veterinary pharmacotherapeutic groupDate of opinion
: date of opinionDecision date
: decision dateRevision number
: revision numberCondition / indication
: condition/indicationSpecies
: species (if veterinary)ATCvet code
: Anatomical Therapeutic Chemical Classification System for veterinary useFirst published
: first publishedRevision date
: revision dateURL
: URL
./scripts
: contains the R scripts used in the analysisanalysis.R
: contains the code used to analyze the data and generate the results and figures presented in the articledata-merging-and-cleaning.R
: contains the code used to clean and merge the raw data from the./data/cost_hospital_level
directory
./figures
: contains the figures generated by theanalysis.R
script in their full resolution
If you find this repository helpful, please consider citing it as follows:
@article{Kostadinov_2024,
title={Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures},
volume={16},
rights={http://creativecommons.org/licenses/by/3.0/},
ISSN={2072-6694},
url={https://www.mdpi.com/2072-6694/16/8/1489},
DOI={10.3390/cancers16081489},
number={8},
journal={Cancers},
author={Kostadinov, Kostadin and Popova-Sotirova, Ivelina and Marinova, Yuliyana and Musurlieva, Nina and Iskrov, Georgi and Stefanov, Rumen},
year={2024},
pages={1489},
language={en}
}